Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marion Smits

Showing results (181-190 of 220) with videos related to

Pageof 22
Sort By:
The Lancet. Oncology|August 18, 2018
Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trialMartin J van den Bent, Martin Klein, Marion Smits, et al.
European Journal of Cancer (Oxford, England : 1990)|April 23, 2015
The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trialLinda Dirven, Martin J van den Bent, Andrew Bottomley, et al.
Neuro-Oncology|August 16, 2022
IDH1/2 wildtype gliomas grade 2 and 3 with molecular glioblastoma-like profile have a distinct course of epilepsy compared to IDH1/2 wildtype glioblastomasMark P van Opijnen, C Mircea S Tesileanu, Linda Dirven, et al.
The Lancet. Oncology|November 3, 2023
A framework for standardised tissue sampling and processing during resection of diffuse intracranial glioma: joint recommendations from four RANO groupsPhilipp Karschnia, Marion Smits, Guido Reifenberger, et al.
Nature Reviews. Clinical Oncology|December 9, 2020
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthoodMichael Weller, Martin van den Bent, Matthias Preusser, et al.
Frontiers in Oncology|January 27, 2022
Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group - ESOI Joint PaperLaure Fournier, Lioe-Fee de Geus-Oei, Daniele Regge, et al.
Neuro-Oncology|November 21, 2019
INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastomaMartin Van Den Bent, Marica Eoli, Juan Manuel Sepulveda, et al.
Neuroimage. Clinical|June 12, 2021
Cross-cohort generalizability of deep and conventional machine learning for MRI-based diagnosis and prediction of Alzheimer's diseaseEsther E Bron, Stefan Klein, Janne M Papma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2017
Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II TrialsBenjamin M Ellingson, Elizabeth R Gerstner, Marion Smits, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 4, 2025
Availability and use of PET in patients with brain tumours - a European Organisation for Research and Treatment of Cancer - Brain Tumour Group (EORTC-BTG) surveyMaximilian J Mair, Philipp Lohmann, Norbert Galldiks, et al.
Pageof 22

Showing results (181-190 of 220) with videos related to

Sort By:
Pageof 22
The Lancet. Oncology|August 18, 2018
Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trialMartin J van den Bent, Martin Klein, Marion Smits, et al.
European Journal of Cancer (Oxford, England : 1990)|April 23, 2015
The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trialLinda Dirven, Martin J van den Bent, Andrew Bottomley, et al.
Neuro-Oncology|August 16, 2022
IDH1/2 wildtype gliomas grade 2 and 3 with molecular glioblastoma-like profile have a distinct course of epilepsy compared to IDH1/2 wildtype glioblastomasMark P van Opijnen, C Mircea S Tesileanu, Linda Dirven, et al.
The Lancet. Oncology|November 3, 2023
A framework for standardised tissue sampling and processing during resection of diffuse intracranial glioma: joint recommendations from four RANO groupsPhilipp Karschnia, Marion Smits, Guido Reifenberger, et al.
Nature Reviews. Clinical Oncology|December 9, 2020
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthoodMichael Weller, Martin van den Bent, Matthias Preusser, et al.
Frontiers in Oncology|January 27, 2022
Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group - ESOI Joint PaperLaure Fournier, Lioe-Fee de Geus-Oei, Daniele Regge, et al.
Neuro-Oncology|November 21, 2019
INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastomaMartin Van Den Bent, Marica Eoli, Juan Manuel Sepulveda, et al.
Neuroimage. Clinical|June 12, 2021
Cross-cohort generalizability of deep and conventional machine learning for MRI-based diagnosis and prediction of Alzheimer's diseaseEsther E Bron, Stefan Klein, Janne M Papma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2017
Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II TrialsBenjamin M Ellingson, Elizabeth R Gerstner, Marion Smits, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 4, 2025
Availability and use of PET in patients with brain tumours - a European Organisation for Research and Treatment of Cancer - Brain Tumour Group (EORTC-BTG) surveyMaximilian J Mair, Philipp Lohmann, Norbert Galldiks, et al.
Pageof 22